The FDA announced on March 23, 2015, that Mylan Institutional LLC is recalling Gemcitabine for Injection, USP vials due to the presence of particulate matter. Owners should stop using the product and contact Mylan for a refund.
How to tell if you have it
- Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial
- NDC 67457-463-02
- UPC 3 67457 46302 5
- Lot #: 7801221, 7801222
- Expiration: 03/16
The hazard
The recall is due to the presence of particulate matter in the vials. The FDA classified this as a Class I recall, indicating a high risk of adverse health consequences.
Context
GovInfoNow's records show Mylan Institutional LLC has 10 other recalls on record since January 23, 2015. Other recent recalls include the Mylan Thiamine HCl Injection recall (May 3, 2021), the Mylan Amiodarone Injection recall (August 17, 2020), and the Mylan Daptomycin Injection recall (July 7, 2020). Other recent recalls of similar products include the IMAAVY Injection recall (September 23, 2026), the Mylan Mycophenolate Mofetil Injection recall (July 2, 2026), and the GE Healthcare Omnipaque 300 mg/mL Injection recall (March 24, 2026).